COMMUNIQUÉS West-GlobeNewswire
-
The Ensign Group Grows Operations in Arizona
03/02/2026 -
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
03/02/2026 -
RadNet Enters Indiana with Acquisition of Northwest Radiology
03/02/2026 -
Tilray Brands Ignites Championship Sunday: Nationwide Tap Room Events, Big Game Day Deals, and Fan Experiences Announced
03/02/2026 -
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
03/02/2026 -
Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
03/02/2026 -
The Ensign Group Obtains Real Estate and Operations in Texas
03/02/2026 -
Peer-reviewed publication validates Cylinder Health savings
03/02/2026 -
CorVel Announces Revenues and Earnings
03/02/2026 -
The Ensign Group Buys Real Estate and Operations in Wisconsin
03/02/2026 -
NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2
03/02/2026 -
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
03/02/2026 -
ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative
03/02/2026 -
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
03/02/2026 -
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
03/02/2026 -
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
03/02/2026 -
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event
03/02/2026 -
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer
03/02/2026 -
Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program
03/02/2026
Pages